title: [Efficacy of cabergoline in the treatment of macroprolactinoma].
authors.forename: O
authors.initials: O
authors.lastname: Dupuy
authors.forename: E
authors.initials: E
authors.lastname: Le Marec
authors.forename: H
authors.initials: H
authors.lastname: Mayaudon
authors.forename: H
authors.initials: H
authors.lastname: Rilminger
authors.forename: L
authors.initials: L
authors.lastname: Bordier
authors.forename: B
authors.initials: B
authors.lastname: Bauduceau
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004873:Ergolines / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D015175:Prolactinoma / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline